On August 28, 2019, the nineteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
On July 15, 2019, the seventeenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
On July 12, 2019, MAPS received a response from the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic …
In June 2019, MAPS responded to the U.S. Food and Drug Administration’s (FDA) continue clinical hold letter regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy …
On June 5, 2019, the fifteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
In May 2019, the U.S. Food and Drug Administration (FDA) sent a formal response to MAPS regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic …
On May 1, 2019, the thirteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
In April 2019, MAPS Public Benefit Corporation (MAPS PBC) sent a response to the clinical hold letter received by the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded …
On March 6, 2019, the twelfth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
In March 2019, MAPS Public Benefit Corporation (MAPS PBC) received a clinical hold letter from the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded Access program …
On February 20, 2019, the fourteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
In January 2019, MAPS Public Benefit Corporation (MAPS PBC) sent a formal protocol to the U.S. Food and Drug Administration (FDA) for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic …
